Alzheimer's research & therapy
-
Alzheimers Res Ther · May 2016
Randomized Controlled Trial Multicenter StudyBapineuzumab for mild to moderate Alzheimer's disease in two global, randomized, phase 3 trials.
Our objective was to evaluate the efficacy (clinical and biomarker) and safety of intravenous bapineuzumab in patients with mild to moderate Alzheimer's disease (AD). ⋯ These phase 3 global trials confirmed lack of efficacy of bapineuzumab at tested doses on clinical endpoints in patients with mild to moderate AD. Some differences in the biomarker results were seen compared with the other phase 3 bapineuzumab trials. No unexpected adverse events were observed.